Morphotek, Inc., a subsidiary of Eisai Co., Ltd., has signed a licensing agreement with Human Monoclonals International, Inc. (HMI) for exclusive rights to a human monoclonal IgM antibody that is specific to a cancer cell surface antigen. Morphotek will use its Morphodoma antibody technology in an effort to develop an optimized lead therapeutic monoclonal antibody and high-titer cell lines suitable for scalable manufacturing.     “This agreement provides yet another important addition to our ...